ANGEL LUIS
GUERRERO PERAL
PROFESOR ASOCIADO CIENCIAS DE LA SALUD
Hospital Universitario de la Princesa
Madrid, EspañaPublikationen in Zusammenarbeit mit Forschern von Hospital Universitario de la Princesa (18)
2024
-
Effectiveness, tolerability, and response predictors of preventive anti-CGRP mAbs for migraine in patients over 65 years old: a multicenter real-world case-control study
Pain Medicine (United States), Vol. 25, Núm. 3, pp. 194-202
-
Long-term safety of OnabotulinumtoxinA treatment in chronic migraine patients: a five-year retrospective study
Frontiers in Neurology , Vol. 15
-
RE-START: Exploring the effectiveness of anti-calcitonin gene-related peptide resumption after discontinuation in migraine
European Journal of Neurology, Vol. 31, Núm. 4
2023
-
Recomendaciones de consenso para el tratamiento de la prevención de la migraña
Farmacia hospitalaria : organo oficial de expresion cientifica de la Sociedad Espanola de Farmacia Hospitalaria, Vol. 47, Núm. 6, pp. 246-253
-
[Translated article] Consensus recommendations on the preventive treatment of migraine
Farmacia Hospitalaria, Vol. 47, Núm. 6, pp. T246-T253
2022
-
Calcitonin gene–related peptide in migraine: from pathophysiology to treatment
Neurologia, Vol. 37, Núm. 5, pp. 390-402
-
Post-COVID-19 persistent headache: A multicentric 9-months follow-up study of 905 patients
Cephalalgia, Vol. 42, Núm. 8, pp. 804-809
2021
-
Effects of the onabotulinumtoxinA follow-up delay in migraine course during the COVID-19 lockdown
Neurological Sciences, Vol. 42, Núm. 12, pp. 5087-5092
-
Evaluation of the Impact of the COVID-19 Lockdown in the Clinical Course of Migraine
Pain medicine (Malden, Mass.), Vol. 22, Núm. 9, pp. 2079-2091
2020
-
Association Between Personality Traits and Onabotulinumtoxin A Response in Patients With Chronic Migraine
Headache, Vol. 60, Núm. 1, pp. 153-161
-
Evaluation of the concomitant use of oral preventive treatments and onabotulinumtoxinA in chronic migraine: the PREVENBOX study
European Journal of Neurology, Vol. 27, Núm. 10, pp. 2102-2108
-
Evidence of and experience with the use of onabotulinumtoxinA in trigeminal neuralgia and primary headaches other than chronic migraine
Neurologia, Vol. 35, Núm. 8, pp. 568-578
2019
-
CALCA and TRPV1 genes polymorphisms are related to a good outcome in female chronic migraine patients treated with OnabotulinumtoxinA
Journal of Headache and Pain, Vol. 20, Núm. 1
-
Evidence and experience with onabotulinumtoxinA in chronic migraine: Recommendations for daily clinical practice
Neurologia, Vol. 34, Núm. 6, pp. 408-417
-
Prediction of patient's response to OnabotulinumtoxinA treatment for migraine
Heliyon, Vol. 5, Núm. 2
-
Real world preventative drug management of migraine among Spanish neurologists
Journal of Headache and Pain, Vol. 20, Núm. 1
-
Wearing off Response to OnabotulinumtoxinA in Chronic Migraine: Analysis in a Series of 193 Patients
Pain Medicine (United States), Vol. 20, Núm. 9, pp. 1815-1821
2018
-
Patterns of anaesthetic pericranial nerve block in headache patients
Neurologia, Vol. 33, Núm. 3, pp. 160-164